NASDAQ:XDNA Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News $7.38 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesOptions ChainRatingsTrends About Kelly CRISPR & Gene Editing Technology ETF (NASDAQ:XDNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XDNA alerts:Sign Up Key Stats Today's Range$7.38▼$7.3850-Day Range$7.38▼$7.3852-Week Range$5.87▼$11.83VolumeN/AAverage Volume3,034 shsMarket Capitalization$2.21 millionAssets Under Management$2.58 millionDividend Yield0.12%Net Expense Ratio0.78%Aggregate RatingModerate Buy ETF OverviewThe Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.Read More… When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Kelly CRISPR & Gene Editing Technology ETF ExpensesTypeXDNATheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.78%0.57%0.55%0.49%0.52%Other Expenses0.00%0.57%0.49%0.41%0.53%Total Expense0.78%0.72%0.71%0.63%0.71%Fee Waiver0.00%-0.73%-0.52%-0.32%-0.57%Net Expense0.78%0.60%0.61%0.56%0.59% Receive XDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kelly CRISPR & Gene Editing Technology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XDNA ETF News HeadlinesWeight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right nowOctober 2, 2024 | yahoo.comK-12 Genome Editing at Only $2 a PopSeptember 27, 2024 | yahoo.comBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. November 21, 2024 | WealthPress (Ad)Vertex Stock: Came For CF Drugs, Staying For Gene TherapyAugust 2, 2024 | seekingalpha.comCRISPR can treat common form of inherited blindness, early data hintMay 15, 2024 | msn.comCRISPR Technology Takes Center Stage at SXSW 2024 for the First TimeMarch 9, 2024 | markets.businessinsider.comSee More Headlines XDNA ETF - Frequently Asked Questions How have XDNA shares performed this year? Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 at the beginning of the year. Since then, XDNA stock has increased by 0.0% and is now trading at $7.38. View the best growth stocks for 2024 here. How do I buy shares of Kelly CRISPR & Gene Editing Technology ETF? Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kelly CRISPR & Gene Editing Technology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kelly CRISPR & Gene Editing Technology ETF investors own include Meta Platforms (META), RTX (RTX), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Cloudflare (NET), Birkenstock (BIRK) and Baidu (BIDU). Fund Details IssuerKelly Strategic Management Fund NameKelly CRISPR & Gene Editing Technology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:XDNA Inception Date1/12/2022 Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkStrategic CRISPR & Gene Editing Technology Index CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings2 Fund Statistics Assets Under Management$2.58 million Average Daily Volume$0.00 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorKelly Strategic Management, LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerJane Street Miscellaneous Outstanding Shares300,000Beta0.92 Creation Unit25,000 Creation Fee$250.00 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Top 10 XDNA HoldingsIntellia Therapeutics (NASDAQ:NTLA)Holding Weight: 11.05%Thermo Fisher Scientific (NYSE:TMO)Holding Weight: 10.70%Beam Therapeutics (NASDAQ:BEAM)Holding Weight: 9.57%CRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 8.64%Caribou Biosciences (NASDAQ:CRBU)Holding Weight: 6.78%Verve Therapeutics (NASDAQ:VERV)Holding Weight: 5.63%Sangamo Therapeutics (NASDAQ:SGMO)Holding Weight: 5.16%Prime Medicine (NYSE:PRME)Holding Weight: 4.73%AbbVie (NYSE:ABBV)Holding Weight: 4.37%Editas Medicine (NASDAQ:EDIT)Holding Weight: 4.13%Full Holdings Details This page (NASDAQ:XDNA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Kelly CRISPR & Gene Editing Technology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
